We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Secondary concern

21 November 2019 By Liam Proud

Cinven, Astorg and Abu Dhabi’s wealth fund are taking a drug-testing group off KKR’s hands. The buyer knows the sector and has a clear M&A-driven plan, but the price is high. With tons of buyout cash and weak IPO markets, such eyebrow-raising “pass the parcel” deals will boom.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)